Read by QxMD icon Read

Alzheimer's Research & Therapy

Laura M Gault, Robert A Lenz, Craig W Ritchie, Andreas Meier, Ahmed A Othman, Qi Tang, Scott Berry, Yili Pritchett, Weining Z Robieson
BACKGROUND: Results from a phase 2a study indicated that treatment with the novel α7 nicotinic acetylcholine receptor agonist ABT-126 25 mg once daily (QD) was associated with a trend for improvement in cognition in subjects with mild-to-moderate Alzheimer's dementia (AD). A phase 2b program was designed to evaluate a broader dose range of ABT-126 as monotherapy in subjects with mild-to-moderate AD. The program consisted of a double-blind, placebo and active controlled study of ABT-126 (dose range 25-75 mg) and an open-label extension study (75 mg)...
October 18, 2016: Alzheimer's Research & Therapy
Rinko Grewal, Mona Haghighi, Shuai Huang, Amanda G Smith, Chuanhai Cao, Xiaoyang Lin, Daniel C Lee, Nancy Teten, Angela M Hill, Maj-Linda B Selenica
BACKGROUND: There is a need to investigate biomarkers that are indicative of the progression of dementia in ethnic patient populations. The disparity of information in these populations has been the focus of many clinical and academic centers, including ours, to contribute to a higher success rate in clinical trials. In this study, we have investigated plasma biomarkers in amnestic mild cognitively impaired (aMCI) female patient cohorts in the context of ethnicity and cognitive status...
October 18, 2016: Alzheimer's Research & Therapy
Stefanie Lerche, Kathrin Brockmann, Andrea Pilotto, Isabel Wurster, Ulrike Sünkel, Markus A Hobert, Anna-Katharina von Thaler, Claudia Schulte, Erik Stoops, Hugo Vanderstichele, Victor Herbst, Britta Brix, Gerhard W Eschweiler, Florian G Metzger, Walter Maetzler, Daniela Berg
BACKGROUND: Mild parkinsonian signs (MPS) are common in older people and are associated with an increased risk of different neurodegenerative diseases. This study prospectively evaluates the longitudinal course of cognitive performance in older individuals with MPS. METHODS: From the TREND study, 480 individuals neurologically healthy at baseline, aged between 50 and 80 years, with complete follow-up data for three assessments within a mean of 43.8 months, were included in this analysis...
October 10, 2016: Alzheimer's Research & Therapy
Annika Öhrfelt, Ann Brinkmalm, Julien Dumurgier, Gunnar Brinkmalm, Oskar Hansson, Henrik Zetterberg, Elodie Bouaziz-Amar, Jacques Hugon, Claire Paquet, Kaj Blennow
BACKGROUND: Synaptic degeneration is a central pathogenic event in Alzheimer's disease that occurs early during the course of disease and correlates with cognitive symptoms. The pre-synaptic vesicle protein synaptotagmin-1 appears to be essential for the maintenance of an intact synaptic transmission and cognitive function. Synaptotagmin-1 in cerebrospinal fluid is a candidate Alzheimer biomarker for synaptic dysfunction that also may correlate with cognitive decline. METHODS: In this study, a novel mass spectrometry-based assay for measurement of cerebrospinal fluid synaptotagmin-1 was developed, and was evaluated in two independent sample sets of patients and controls...
October 3, 2016: Alzheimer's Research & Therapy
Laure Saint-Aubert, Ove Almkvist, Konstantinos Chiotis, Rita Almeida, Anders Wall, Agneta Nordberg
BACKGROUND: The recent development of tau-specific positron emission tomography (PET) tracers has allowed in vivo quantification of regional tau deposition and offers the opportunity to monitor the progression of tau pathology along with cognitive impairment. In this study, we investigated the relationships of cerebral tau deposition ([(18)F]THK5317-PET) and metabolism ([(18)F]FDG-PET) with concomitant cognitive function in patients with probable Alzheimer's disease (AD). METHODS: Nine patients diagnosed with AD dementia and 11 with prodromal AD (mild cognitive impairment, amyloid-positive on [(11)C]PiB-PET) were included in this study...
September 29, 2016: Alzheimer's Research & Therapy
Jeffrey Cummings, Paul S Aisen, Bruno DuBois, Lutz Frölich, Clifford R Jack, Roy W Jones, John C Morris, Joel Raskin, Sherie A Dowsett, Philip Scheltens
The global impact of Alzheimer's disease (AD) continues to increase, and focused efforts are needed to address this immense public health challenge. National leaders have set a goal to prevent or effectively treat AD by 2025. In this paper, we discuss the path to 2025, and what is feasible in this time frame given the realities and challenges of AD drug development, with a focus on disease-modifying therapies (DMTs). Under the current conditions, only drugs currently in late Phase 1 or later will have a chance of being approved by 2025...
2016: Alzheimer's Research & Therapy
Shuman Zhang, Pan Wang, Lili Ren, Chunli Hu, Jing Bi
BACKGROUND: Amyloid-beta (Aβ) plays a key role in Alzheimer's disease (AD) pathogenesis, and soluble Aβ oligomers are more cytotoxic than Aβ fibrils. Recent evidence suggests that Notch signaling is affected by AD and other brain diseases. Melatonin exerts beneficial effects on many aspects of AD and may protect against myocardial ischemia via Notch1 signaling regulation. Therefore, we hypothesized that the Notch1 signaling pathway is involved in the neuroprotective role of melatonin against soluble Aβ1-42...
2016: Alzheimer's Research & Therapy
Rosa M Sancho, Carla J Cox, Laura E Phipps, Simon H Ridley
The annual Alzheimer's Research UK (ARUK) Conference was hosted by the Manchester and North West Network Centre on March 8-9, 2016. In this report, we provide a summary of the research presented.
2016: Alzheimer's Research & Therapy
Michel Maitre, Christian Klein, Ayikoe G Mensah-Nyagan
Gamma-hydroxybutyrate (GHB or Xyrem(R)) is frequently used in humans for several clinical indications, including anesthesia, narcolepsy/cataplexy, and alcohol-withdrawal symptoms. Pharmacological effects induced in the brain by therapeutic doses of Xyrem(R) are generally GABAergic-dependent. These effects allow sedation, stress/anxiety reduction, deep sleep induction, decrease of neuroinflammation, and neuroprotection. Furthermore, Xyrem(R) promotes the expression of pivotal genes reducing toxic proteinopathies, as demonstrated in laboratory animal models...
2016: Alzheimer's Research & Therapy
Susan Fromholt, Christian Reitano, Hilda Brown, Jada Lewis, David R Borchelt
BACKGROUND: Targeting the expression of genes has emerged as a potentially viable therapeutic approach to human disease. In Alzheimer's disease, therapies that silence the expression of tau could be a viable strategy to slow disease progression. METHODS: We produced a novel strain of transgenic mice that could be used to assess the efficacy of gene knockdown therapies for human tau, in live mice. We designed a tetracycline-regulated transgene construct in which the cDNA for human tau was fused to ubiquitin and to luciferase to create a single fusion polyprotein, termed TUL...
2016: Alzheimer's Research & Therapy
Jean-François Blain, Matthew G Bursavich, Emily A Freeman, Lori A Hrdlicka, Hilliary E Hodgdon, Ting Chen, Don E Costa, Bryce A Harrison, Sudarshan Kapadnis, Deirdre A Murphy, Scott Nolan, Zhiming Tu, Cuyue Tang, Duane A Burnett, Holger Patzke, Gerhard Koenig
BACKGROUND: Familial Alzheimer's disease (FAD) is caused by mutations in the amyloid precursor protein (APP) or presenilin (PS). Most PS mutations, which account for the majority of FAD cases, lead to an increased ratio of longer to shorter forms of the amyloid beta (Aβ) peptide. The therapeutic rationale of γ-secretase modulators (GSMs) for Alzheimer's disease is based on this genetic evidence as well as on enzyme kinetics measurements showing changes in the processivity of the γ-secretase complex...
2016: Alzheimer's Research & Therapy
Penny A Dacks, Joshua J Armstrong, Stephen K Brannan, Aaron J Carman, Allan M Green, M Sue Kirkman, Lawrence R Krakoff, Lewis H Kuller, Lenore J Launer, Simon Lovestone, Elizabeth Merikle, Peter J Neumann, Kenneth Rockwood, Diana W Shineman, Richard G Stefanacci, Priscilla Velentgas, Anand Viswanathan, Rachel A Whitmer, Jeff D Williamson, Howard M Fillit
Common diseases like diabetes, hypertension, and atrial fibrillation are probable risk factors for dementia, suggesting that their treatments may influence the risk and rate of cognitive and functional decline. Moreover, specific therapies and medications may affect long-term brain health through mechanisms that are independent of their primary indication. While surgery, benzodiazepines, and anti-cholinergic drugs may accelerate decline or even raise the risk of dementia, other medications act directly on the brain to potentially slow the pathology that underlies Alzheimer's and other dementia...
2016: Alzheimer's Research & Therapy
Rita Banzi, Paolo Camaioni, Mauro Tettamanti, Vittorio Bertele', Ugo Lucca
BACKGROUND: The age gap between participants in trials and patients who could benefit from the drugs studied has been widely documented across different clinical areas. Patients with dementia included in clinical research are systematically younger than those in the general population. We examined the age gap between participants in recent clinical trials testing interventions for Alzheimer's disease and epidemiological data. METHODS: We systematically searched literature databases (MedLine, EMBASE, the Cochrane Library) and ClinicalTrials...
2016: Alzheimer's Research & Therapy
Frederic Blanc, Sean J Colloby, Benjamin Cretin, Paulo Loureiro de Sousa, Catherine Demuynck, John T O'Brien, Catherine Martin-Hunyadi, Ian McKeith, Nathalie Philippi, John-Paul Taylor
BACKGROUND: Little is known about the patterns of brain atrophy in prodromal dementia with Lewy bodies (pro-DLB). METHODS: In this study, we used SPM8 with diffeomorphic anatomical registration through exponentiated lie algebra to measure grey matter (GM) volume and investigate patterns of GM atrophy in pro-DLB (n = 28) and prodromal Alzheimer's disease (pro-AD) (n = 27) and compared and contrasted them with those in elderly control subjects (n = 33) (P ≤ 0...
2016: Alzheimer's Research & Therapy
N Philippi, V Noblet, E Duron, B Cretin, C Boully, I Wisniewski, M L Seux, C Martin-Hunyadi, E Chaussade, C Demuynck, S Kremer, S Lehéricy, D Gounot, J P Armspach, O Hanon, F Blanc
BACKGROUND: The aim of this volumetric study was to explore the neuroanatomical correlates of the Free and Cued Selective Reminding Test (FCSRT) and the Delayed Matching-to-Sample-48 items (DMS-48), two tests widely used in France to assess verbal and visual anterograde memory. We wanted to determine to what extent the two tests rely on the medial temporal lobe, and could therefore be predictive of Alzheimer's disease, in which pathological changes typically start in this region. METHODS: We analysed data from a cohort of 138 patients with mild cognitive impairment participating in a longitudinal multicentre clinical research study...
2016: Alzheimer's Research & Therapy
Martin Prince, Gemma-Claire Ali, Maëlenn Guerchet, A Matthew Prina, Emiliano Albanese, Yu-Tzu Wu
BACKGROUND: Current projections of the scale of the coming dementia epidemic assume that the age- and sex-specific prevalence of dementia will not vary over time, and that population ageing alone (increasing the number of older people at risk) drives the projected increases. The basis for this assumption is doubtful, and secular trends (that is, gradual decreases or increases in prevalence over long-term periods) are perfectly plausible. METHODS: We carried out a systematic review of studies of trends in prevalence, incidence and mortality for people with dementia, conducted since 1980...
2016: Alzheimer's Research & Therapy
Daniel Roquet, Marion Sourty, Anne Botzung, Jean-Paul Armspach, Frédéric Blanc
BACKGROUND: We aimed to describe specific changes in brain perfusion in patients with dementia with Lewy bodies (DLB) at both the prodromal (also called mild cognitive impairment) and mild dementia stages, relative to patients with Alzheimer's disease (AD) and controls. METHODS: Altogether, 96 participants in five groups (prodromal DLB, prodromal AD, DLB with mild dementia, AD with mild dementia, and healthy elderly controls) took part in an arterial spin labeling MRI study...
2016: Alzheimer's Research & Therapy
Helga Eyjolfsdottir, Maria Eriksdotter, Bengt Linderoth, Göran Lind, Bengt Juliusson, Philip Kusk, Ove Almkvist, Niels Andreasen, Kaj Blennow, Daniel Ferreira, Eric Westman, Inger Nennesmo, Azadeh Karami, Taher Darreh-Shori, Ahmadul Kadir, Agneta Nordberg, Erik Sundström, Lars-Olof Wahlund, Anders Wall, Maria Wiberg, Bengt Winblad, Åke Seiger, Lars Wahlberg, Per Almqvist
BACKGROUND: Targeted delivery of nerve growth factor (NGF) has emerged as a potential therapy for Alzheimer's disease (AD) due to its regenerative effects on basal forebrain cholinergic neurons. This hypothesis has been tested in patients with AD using encapsulated cell biodelivery of NGF (NGF-ECB) in a first-in-human study. We report our results from a third-dose cohort of patients receiving second-generation NGF-ECB implants with improved NGF secretion. METHODS: Four patients with mild to moderate AD were recruited to participate in an open-label, phase Ib dose escalation study with a 6-month duration...
2016: Alzheimer's Research & Therapy
Lin Tan, Lan Tan, Hui-Fu Wang, Jun Wang, Chen-Chen Tan, Meng-Shan Tan, Xiang-Fei Meng, Chong Wang, Jin-Tai Yu
No abstract text is available yet for this article.
2016: Alzheimer's Research & Therapy
Hussein N Yassine, Varun Rawat, Wendy J Mack, Joseph F Quinn, Karin Yurko-Mauro, Eileen Bailey-Hall, Paul S Aisen, Helena C Chui, Lon S Schneider
BACKGROUND: Apolipoprotein E (APOE) ɛ4 and low cerebrospinal fluid (CSF) amyloid-β42 (Aβ42) levels are predictors for developing Alzheimer's disease (AD). The results of several studies indicate an interaction between docosahexaenoic acid (DHA) consumption and cognitive outcomes by APOE genotype. Our objective in the present study was to examine whether APOE ɛ4 genotype and low CSF Aβ42 levels were associated with reduced delivery of DHA to CSF in the Alzheimer's Disease Cooperative Study-sponsored DHA clinical trial...
2016: Alzheimer's Research & Therapy
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"